Biopharmaceutical Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Biopharmaceutical stocks.

Biopharmaceutical Stocks Recent News

Date Stock Title
Nov 20 HAYN Dream Finders Homes Set to Join S&P SmallCap 600
Nov 20 ARGX argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Nov 19 BMY Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)
Nov 19 BMY Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
Nov 18 BMY Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Nov 18 BMY Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now?
Nov 18 ARGX Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?
Nov 18 GRCE GRCE: FY:25 Second Quarter Results
Nov 18 BMY EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
Nov 17 CDMO Avid Bioservices, Inc. (CDMO): A Bull Case Theory
Nov 17 BMY Bristol-Myers Squibb: Buy This Bargain Before It's Gone
Nov 17 BMY Large Pension Doubled Palantir Stake, Bought Up Intel and CVS Stock
Nov 15 BMY Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS
Nov 15 CDMO Avid Bioservices gains as holder opposes $12.50 a share takeover
Nov 15 GRCE Grace Therapeutics And 2 Other US Penny Stocks To Watch
Nov 15 BMY Bristol Myers gets positive EMA opinion for repotrectinib
Nov 15 BMY Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Nov 15 BMY Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
Nov 14 BMY Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug
Nov 14 BMY Tudor Investment adds Infinera, Trane, exits Disney, UnitedHealth, among top Q3 trades
Biopharmaceutical

A biopharmaceutical, also known as a biologic(al) medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial.

Browse All Tags